Abiomed Announces Expanded Heart Recovery Strategy with Multi Year Growth Initiatives

Abiomed, Inc.

today presented its expanded heart recovery strategy along with new initiatives that are expected to enhance strong, multi-year double digit sales and earnings growth. During its annual investor and analyst day in New York City, Abiomed will discuss the recently announced PROTECT II clinical and economic developments, the new Symphony™ product, the Company's strategy for long term growth and its new technology pipeline. Specifically, the Company announced a new higher flow Impella device, named Impella cVAD™. Commercial U.S. availability is planned for the summer of 2012. The Company also provided updates on its strategy for market entry into Japan, and announced an estimated Impella market entry timing of 2013. Currently, approximately 25,000 patients are treated in Japan with the intra-aortic balloon pump.